Skip to content

Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis

Detection of Clonal Mast Cell Disorders Among Patients With Exercise-induced Anaphylaxis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01326741
Enrollment
10
Registered
2011-03-31
Start date
2011-03-31
Completion date
Unknown
Last updated
2011-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaphylaxis

Keywords

clonal mast cell disorder, exercise-induced anaphylaxis, hypotension

Brief summary

Anaphylaxis is a serious allergic reaction that develops rapidly and can cause death. Some patients experience anaphylaxis is association with exercise, a disorder called exercise-induced anaphylaxis. A subset of patients with unexplained anaphylaxis, especially those with hypotension during the anaphylactic episodes, have been shown to have abnormal, clonal populations of a certain cell type, mast cells, in the bone marrow. This has been described in at least one patient with exercise-induced anaphylaxis. The investigators would like review the findings in a group of patients with exercise-induced anaphylaxis who have undergone evaluation for the presence of abnormal, clonal mast cells.

Interventions

None listed

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Anaphylaxis in association with exercise on at least two occasions * During anaphylactic reaction, the subject must have experienced one or more of the following: flushing, hypotension, lack of urticaria

Exclusion criteria

* Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with presence of clonal abnormalities in the bone marrow specimenBaselinePresence of clonal mast cells in bone marrow as assessed by D816V c-kit mutation or CD25 will be recorded for each participant.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026